Resistance mutation info of target
| Target General Information | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Target ID | T58454 | |||||||||||||||||
| Target Name | Fibroblast growth factor receptor 2 (FGFR2) | |||||||||||||||||
| Gene Name | FGFR2 | |||||||||||||||||
| Species | Homo sapiens | |||||||||||||||||
| UniProt ID | FGFR2_HUMAN | |||||||||||||||||
| Sequence |
MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV RCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF MVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI NHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK YGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL PAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK RIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK LTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM IGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF KDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT TNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH RMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT [Homo sapiens] |
|||||||||||||||||
| Drug and Corresponding Resistance Mutations | ||||||||||||||||||
| Mutation Info | Missense: E566G | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| Mutation Info | Missense: I548V | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| Mutation Info | Missense: K660E | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| Mutation Info | Missense: L618M | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| Mutation Info | Missense: M536I | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| Mutation Info | Missense: M538I | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| Mutation Info | Missense: V565I | |||||||||||||||||
| Drugs |
|
|||||||||||||||||
| References | ||||||||||||||||||
| REF 1 | The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. 2013 Aug;15(8):975-88. | |||||||||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.